Dr. Martens (LON:DOCS) Stock Price Down 12.6% – Here’s What Happened

Dr. Martens plc (LON:DOCS)’s share price fell 12.6% on Tuesday . The stock traded as low as GBX 65 and last traded at GBX 66.10. 4,806,140 shares were traded during mid-day trading, an increase of 166% from the average session volume of 1,808,856 shares. The stock had previously closed at GBX 75.65.

Trending Headlines about Dr. Martens

Here are the key news stories impacting Dr. Martens this week:

• Positive Sentiment: Berenberg reaffirmed a “buy” rating on DOCS, which supports a constructive view from at least one broker and can provide a floor for sentiment. Berenberg Buy Reaffirmed Broker Notes on LSE
• Neutral Sentiment: Trading showed elevated volume vs. average, suggesting the move is driven by active repositioning rather than thin liquidity; keep an eye on follow-through volume and whether buy-side interest re-emerges. (Background: DOCS has a relatively high P/E and leverage that can amplify sentiment-driven moves.)
• Negative Sentiment: Management now expects flat revenue for fiscal 2026 as it scales back discounting — this signals weaker top‑line growth than investors may have hoped, even if margin benefits from fewer discounts are possible; the guidance is the primary driver of the negative market reaction. Dr Martens projects flat 2026 revenue

Analyst Ratings Changes

Several research firms recently issued reports on DOCS. Berenberg Bank reiterated a “buy” rating on shares of Dr. Martens in a research report on Tuesday. Peel Hunt reiterated a “buy” rating on shares of Dr. Martens in a research report on Thursday, November 20th. Two investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of GBX 6,000.

Dr. Martens Price Performance

The company has a quick ratio of 1.13, a current ratio of 2.85 and a debt-to-equity ratio of 127.27. The company has a market capitalization of £646.63 million, a PE ratio of 39.35, a price-to-earnings-growth ratio of 6.40 and a beta of 0.11. The firm’s 50 day simple moving average is GBX 76.53 and its 200 day simple moving average is GBX 83.47.

Dr. Martens (LON:DOCS) last released its quarterly earnings results on Thursday, November 20th. The company reported GBX (0.90) EPS for the quarter. Dr. Martens had a return on equity of 18.91% and a net margin of 7.89%. As a group, research analysts anticipate that Dr. Martens plc will post 2.5809394 EPS for the current fiscal year.

Insider Buying and Selling at Dr. Martens

In other Dr. Martens news, insider Robert Hanson acquired 96,000 shares of the company’s stock in a transaction that occurred on Friday, December 5th. The stock was bought at an average price of GBX 79 per share, for a total transaction of £75,840. Insiders purchased 97,130 shares of company stock valued at $7,673,816 in the last quarter. Corporate insiders own 2.79% of the company’s stock.

Dr. Martens Company Profile

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally
produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical
movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over
60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and
wholesale channels, and in addition to its world-renowned “1460” boot its product segments span shoes including the
1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and
accessories.

The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and
is a constituent of the FTSE 250 index.